1. Home
  2. CCEL vs EVAX Comparison

CCEL vs EVAX Comparison

Compare CCEL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.42

Market Cap

27.8M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$4.06

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
EVAX
Founded
1989
2008
Country
United States
Denmark
Employees
N/A
46
Industry
Managed Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8M
32.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
CCEL
EVAX
Price
$3.42
$4.06
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
7.6K
29.4K
Earning Date
04-14-2026
05-07-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$25,384,279.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
$355.00
N/A
Revenue Growth
9.76
N/A
52 Week Low
$2.72
$1.68
52 Week High
$5.52
$12.15

Technical Indicators

Market Signals
Indicator
CCEL
EVAX
Relative Strength Index (RSI) 46.18 44.97
Support Level $3.18 $3.96
Resistance Level $3.57 $4.65
Average True Range (ATR) 0.18 0.26
MACD -0.02 -0.06
Stochastic Oscillator 2.04 12.92

Price Performance

Historical Comparison
CCEL
EVAX

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: